xanomeline has been researched along with amyloid beta-peptides in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, S; Duan, Y; Jia, K; Li, Z; Wang, D; Zhou, Z | 1 |
1 other study(ies) available for xanomeline and amyloid beta-peptides
| Article | Year |
|---|---|
Xanomeline derivative EUK1001 attenuates Alzheimer's disease pathology in a triple transgenic mouse model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line; Cerebral Cortex; Disease Models, Animal; Exploratory Behavior; Female; Gene Expression; Hippocampus; Male; Maze Learning; Mice; Mice, Transgenic; Neurons; Neuroprotective Agents; Nootropic Agents; Peptide Fragments; Pyridines; Thiadiazoles | 2017 |